Immunome, Inc. (IMNM)
After hours:
| Previous Close | 14.66 |
| Open | 14.76 |
| Bid | 14.20 x 400 |
| Ask | 14.35 x 200 |
| Day's Range | 14.20 - 14.92 |
| 52 Week Range | 4.44 - 30.96 |
| Volume | |
| Avg. Volume | 800,024 |
| Market Cap | 851.836M |
| Beta (5Y Monthly) | 1.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.38 |
| Earnings Date | May 03, 2024 - May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.33 |
Business WireImmunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
BOTHELL, Wash., April 05, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activation protein (FAP). Jack Higgins, PhD, Chief Scientific Officer at Immunome, will present the data in a poster at the American Association for Cancer Research (AACR) Annual Meetin
ZacksNew Strong Sell Stocks for April 4th
IMNM, SLOIF and TMQ have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2023.
Business WireImmunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
BOTHELL, Wash., March 28, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments.
